Basit öğe kaydını göster

dc.contributor.authorALKAN, Sena
dc.contributor.authorKUTLUBAY, Zekayi
dc.contributor.authorÇETİNKALE, Oğuz
dc.contributor.authorSALTOĞLU, Neşe
dc.contributor.authorTABAK, Ömer Fehmi
dc.contributor.authorMETE, Bilgül
dc.contributor.authorMURT, Ahmet
dc.contributor.authorOzdemir, Yusuf Emre
dc.contributor.authorBALKAN, İlker İnanç
dc.contributor.authorBayramlar, Osman Faruk
dc.contributor.authorKARAALİ, Rıdvan
dc.contributor.authorKUŞKUCU, Mert Ahmet
dc.contributor.authorAYGÜN, Gökhan
dc.contributor.authorKESKİNDEMİRCİ, Yılmaz
dc.contributor.authorÖNGÖREN, Şeniz
dc.date.accessioned2021-12-10T12:57:50Z
dc.date.available2021-12-10T12:57:50Z
dc.date.issued2021
dc.identifier.citationOzdemir Y. E. , BALKAN İ. İ. , Bayramlar O. F. , ALKAN S., MURT A., KARAALİ R., METE B., KUŞKUCU M. A. , AYGÜN G., KESKİNDEMİRCİ Y., et al., "Clinical Characteristics of Mild-Moderate COVID-19 Patients and Risk Factors for the Development of Pneumonia", MIKROBIYOLOJI BULTENI, cilt.55, sa.3, ss.342-356, 2021
dc.identifier.issn0374-9096
dc.identifier.otherav_e4f5366e-04ac-4f98-a63d-bcb916676ee2
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/175098
dc.identifier.urihttps://doi.org/10.5578/mb.20219805
dc.description.abstractLimited data exists to date on the predictors for the development of pneumonia in patients with mild and moderate coronavirus (COVID-19). In this study, it was aimed to evaluate the demographic characteristics and clinical findings of mild and moderate COVID-19 and to determine the risk factors for the development of COVID-19 pneumonia in patients admitted to the pandemic outpatient clinic of a university hospital. A total of 414 patients with laboratory confirmed COVID-19 were included. Of these, 220 (53.1%) were male, the mean age was 38.3 +/- 12.7. Median duration of hospital admission from the onset of symptoms was three days (0-11). Of the confirmed COVID-19 cases, 154 (37.2%) had a history of family contact and the most common symptoms were weakness (68.4%), myalgia (61.8%), headache (56.5%), loss of smell (45.2%), loss of taste (43.2%) and anorexia (42.8%). Among females, weakness (p= 0.016), headache (p= 0.008), sore throat (p= 0.032), nausea (p= 0.003), anorexia (p= 0.045), loss of taste (p= 0.005) and loss of smell (p30 were high, and 60.9% of the patients had pneumonia (p< 0.001). CRP (p< 0.001), D-dimer (p= 0.010) values were low, lymphocyte count (p= 0.001) was high among 106 (25.6%) active smokers, and 15.6% of the patients had pneumonia (p< 0.001). Of the patients reported with persistent symptoms, 25.9% had loss of smell, 25% had weakness, and 23.1% had loss of taste on the seventh day; 21.1% had loss of smell, 21.1% had myalgia, and 19.7% had loss of taste on the 14th day. During their follow-up, the COVID-19 polymerase chain reaction (PCR) test was studied in 286 patients for control purposes. The median time of being negative for COVID-19 PCR test was eight days (3-56). In conclusion, symptoms may last longer than 14 days in 20-30% of patients presenting with mild-moderate clinical findings. In addition, obesity should be considered as an important risk factor for COVID-19 pneumonia.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTemel Bilimler
dc.titleClinical Characteristics of Mild-Moderate COVID-19 Patients and Risk Factors for the Development of Pneumonia
dc.typeMakale
dc.relation.journalMIKROBIYOLOJI BULTENI
dc.contributor.departmentBakirkoy Dr. Sadi Konuk Research & Training Hospital , ,
dc.identifier.volume55
dc.identifier.issue3
dc.identifier.startpage342
dc.identifier.endpage356
dc.contributor.firstauthorID2696007


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster